Articles related to BLOOD CANCERS

This study introduces a pivotal model that aids physicians in making informed decisions regarding bone marrow sampling for MGUS patients, utilizing a comprehensive set of biomarkers to predict the progression to SMM or worse conditions with high accuracy.

Imetelstat has shown promising results in improving the quality of life for MDS patients by significantly reducing transfusion dependency, a critical consideration in the management of this blood disorder.

Epcoritamab represents a significant breakthrough in the treatment of Richter syndrome, showcasing promising results in patients who have exhausted other therapeutic avenues. Its unique bispecific action heralds a new era in hematologic malignancy management.

With more than 27,000 doses administered, CAR T-cell therapies represent a breakthrough in treating hematologic malignancies, though emerging reports of secondary T-cell cancers post-treatment highlight the importance of long-term patient monitoring and reporting.

Recent advances in CAR T-cell therapy show significant promise in treating both blood cancers and solid tumors, offering durable responses and extended survival rates for patients previously facing limited options.

Discover how system failures at Messino Cancer Centers have led to a critical decision impacting patient care. Learn more about this significant development and its implications for healthcare delivery.